BPAP

(-)1-(Benzofuran-2-yl)-2-propylaminopentane, designated (-)BPAP and also known by the developmental code FPFS-1169, is a synthetic monoaminergic activity enhancer (MAE) structurally derived from phenylpropylaminopentane (PPAP) through replacement of the phenyl ring with a benzofuran heterocycle. First described by Jozsef Knoll and colleagues in 1999, BPAP represents the most potent synthetic enhancer substance characterized to date, approximately 130-fold more potent than selegiline ((-)-deprenyl) in antagonizing tetrabenazine-induced performance inhibition in the rat shuttle box paradigm, and is the first enhancer substance to augment serotonergic neurotransmission in addition to the catecholaminergic enhancement shared with selegiline and PPAP. The compound selectively amplifies the quantity of dopamine, norepinephrine, and serotonin released per nerve impulse from monoaminergic neurons without inducing spontaneous (impulse-independent) neurotransmitter release, a pharmacological property that distinguishes it fundamentally from amphetamine-type releasing agents and from monoamine oxidase inhibitors. The mechanism of the enhancer effect has been attributed, on the basis of pharmacological antagonism studies using the selective antagonist EPPTB, to agonism at trace amine-associated receptor 1 (TAAR1), which triggers PKC-dependent phosphorylation of SNARE complex proteins and vesicular monoamine transporter 2 (VMAT2), thereby increasing vesicular monoamine accumulation and exocytotic release. At substantially higher concentrations, BPAP also inhibits monoamine reuptake (predominantly dopamine and norepinephrine), though this activity is not considered pharmacologically relevant at the low nanogram-per-milliliter concentrations that produce the enhancer effect. In preclinical pharmacology, BPAP has demonstrated neuroprotective activity against N-methyl(R)salsolinol-induced apoptosis in human dopaminergic SH-SY5Y neuroblastoma cells through stabilization of mitochondrial membrane potential and upregulation of anti-apoptotic Bcl-2 protein expression. The compound upregulates synthesis and secretion of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) in cultured mouse astrocytes, with NGF secretion increased up to 120-fold over control at optimal concentrations. In longevity studies conducted by Knoll and Miklya, subcutaneous administration of BPAP at 0.0001 mg/kg three times weekly from the 10th week of life significantly extended lifespan in male Wistar rats (P < 0.02) and suppressed spontaneous fibromyxosarcoma manifestation from 50 percent (saline controls) to 20 percent (P < 0.001). Pharmacokinetic characterization in rats indicates oral bioavailability with peak plasma levels at 30 to 60 minutes, a secondary peak at approximately 4 hours consistent with enterohepatic recirculation, a terminal elimination half-life of 5.5 to 5.8 hours, blood-brain barrier penetration with distribution to multiple brain regions, and predominantly urinary excretion with greater than 90 percent recovery in excreta within 72 hours. No human clinical trials have been conducted with BPAP as of the date of this monograph. The compound remains an investigational research tool with potential therapeutic relevance to neurodegenerative disease (Parkinson's disease, Alzheimer's disease), depression, and age-related cognitive decline. This monograph reviews the chemistry, synthesis, and stereochemistry of BPAP; the enhancer pharmacology in molecular and neurochemical detail including the TAAR1 mechanism; comprehensive preclinical pharmacokinetics; the neuroprotective, neurotrophic, and longevity evidence; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five monoaminergic activity enhancer and related catecholaminergic compounds against BPAP on five competency standards.